A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

Inclusion Criteria: 1. ≥18 years of age; 2. Solid Tumor confirmed by histology or cytology; 3. ECOG score is 0 or 1; 4. An expected survival of ≥ 12 weeks; 5. At least one measurable lesion according to RECIST v1.1 criteria; 6. Have adequate renal and hepatic function; 7. Patients voluntarily joined the study and signed informed consent. Exclusion Criteria: 1. With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer; 2. Patients have major surgical procedures or radiotherapy / chemotherapy within 4 weeks before the first medication; 3. History of immunodeficiency; 4. Clinically significant cardiovascular diseases; 5. Known or suspected interstitial lung disease; 6. Known hereditary or acquired bleeding thrombotic tendency; 7. Active hepatitis and liver cirrhosis; 8. Known allergic history of the drug components of this protocol; 9. History of neurological or psychiatric disorders.